Connect with us

Hi, what are you looking for?

Economy

Philippines to start clinical trials on ivermectin, other drugs for COVID-19

MANILA – The Philippines will begin clinical trials of several drugs, including the anti-parasite medication ivermectin, in patients with COVID-19 to determine their efficacy in combatting the coronavirus, a senior government official said.

Some politicians in the Philippines have started promoting the use of ivermectin for coronavirus and given out free doses, although the country’s food and drugs regulator has cautioned against the use because of a lack of evidence for the drug as a treatment.

The clinical trial for ivermectin, which could last for six months, “will give us a more reliable estimate of the effects of ivermectin as an anti-viral agent in mild and moderate (COVID-19) patients,” science and technology minister, Fortunato Dela Pena, said in a presentation late on Monday.

The Southeast Asian nation, which is facing one of the worst coronavirus outbreaks in Asia, is battling a renewed surge in infections, with its vaccination drive on reaching 1.3 million people out of its more than 108 million population.

Ivermectin tablets have been approved for treating some worm infestations and for veterinary use in animals for parasites.

The World Health Organization last month recommended against using ivermectin in patients with COVID-19 except for clinical trials, because of a lack of data demonstrating its benefits.

Dela Pena said the government has also approved the clinical trials of a new formulation of methylprednisolone, a steroid, and melatonin, as treatments for COVID-19.

The government will also start trials of an herbal supplement, derived from the native tawa-tawa plant that can fight dengue, he said, adding to ongoing tests using virgin coconut oil for severe COVID-19 patients.

“We are trying several (medications). They may not be vaccines but they could potentially speed up the recovery,” Dela Pena said.

The Philippines has recorded more than 945,000 COVID-19 cases and over 16,000 deaths, the second highest rates in Southeast Asia, next to Indonesia. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

Benigno S.C. Aquino III, the Philippine president who tried to send corrupt officials to jail and took China to court for its island-building activities...

Economy

Personalities took to social media and their respective platforms to express their grief over the death of former President Benigno S. C. Aquino III on Thursday....

Economy

Cloud-based solutions support organizations in terms of collaboration and productivity during the current remote work challenges. As the usage of these tools continues to...

Economy

By Luz Wendy T. Noble, Reporter THE Philippines’ overall balance of payments (BoP) position posted a deficit of $1.39 billion in May, as the...

Economy

National Economic and Development Authority (NEDA) Secretary Karl Kendrick T. Chua stressed the need to fast-track the vaccination of workers to allow the economy...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Economy

US President Joseph R. Biden, Jr., will rely on ally countries to supply the bulk of the metals needed to build electric vehicles and focus on...

Economy

THE Securities and Exchange Commission (SEC) has warned the public from investing or to stop any investment in a group named Maxxprofit Computer Trading...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.



Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!